Previous 10 | Next 10 |
NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
Allena Pharmaceuticals (ALNA) -9.8% premarket after saying it will increase the size of its previously announced $10M bought deal offering.The company has upsized the public offering of 10.4M common shares at $1.25/share, for gross proceeds of ~$13M (from $10M).Underw...
Ovid Therapeutics (OVID) -51% after it misses goal in Angelman syndrome treatment.FuelCell Energy (FCEL) -25% after discloses below-consensus FQ4 revenues; to launch offering.Workhorse Group (WKHS) -22% after Trucks.com reports of further delays in the ...
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, a...
Allena Pharmaceuticals (ALNA) announces bought deal offering of 8M shares at $1.25/share, compared to the stock's yesterday close of $1.35. Gross proceeds expected to be ~$10M. Underwriters have also been given overallotment option for an additional purchase of 1.2M shares.The company in...
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, a...
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
Allena Pharmaceuticals ([[ALNA]] +2.1%) has announced data from its Phase 1 trial evaluating ALLN-346 in healthy volunteers, demonstrating ALLN-346 was well-tolerated with no clinically significant safety signals and no dose-limiting toxicities observed in any cohort up to the highe...
-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Co...
NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...
News, Short Squeeze, Breakout and More Instantly...
Allena Pharmaceuticals Inc. Company Name:
ALNA Stock Symbol:
NASDAQ Market:
Allena Pharmaceuticals Inc. Website:
Buying Penny Stocks on July 29th? Here’s What You Need to Know If you’re looking for the best penny stocks to buy right now, there are hundreds of options to choose from. As a result, it all comes down to finding the best penny stocks that fit your trading strateg...
NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme the...
NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorde...